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Abstract
Background: Intermittent preventive (or presumptive) treatment of infants (IPTi), the
administration of a curative anti-malarial dose to infants whether or not they are known to be
infected, is being considered as a new strategy for malaria control. Five of the six trials using
sulphadoxine-pyrimethamine (SP) for IPTi showed protective efficacies (PEs) against clinical malaria
ranging from 20.1 – 33.3% whilst one, the Ifakara study, showed a protective efficacy of 58.6%.
Materials and methods: The possible mechanisms that could explain the differences in the
reported PE of IPTi were examined by comparing output from a mathematical model to data from
the six published IPTi trials.
Results: Under stable transmission, the PE of IPTi predicted by the model was comparable with
the observed PEs in all but the Ifakara study (ratio of the mean predicted PE to that observed was
1.02, range 0.39 – 1.59). When a reduction in the incidence of infection during the study was
included in the model, the predicted PE of IPTi increased and extended into the second year of life,
as observed in the Ifakara study.
Conclusion: A decrease in malaria transmission during the study period may explain part of the
difference in observed PEs of IPTi between sites and the extended period of protection into the
second year of life observed in the Ifakara study. This finding of continued benefit of interventions
in settings of decreasing transmission may explain why rebound of clinical malaria was absent in the
large scale trials of insecticide-treated bed nets.
Background
Intermittent preventive treatment of infants (IPTi) is the
administration of a curative anti-malarial dose to infants,
whether or not they are known to be infected, at specified
times to prevent malaria [1]. IPTi delivered through the
EPI programme was first shown to successfully prevent
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ine-pyrimethamine (SP) given to Tanzanian infants living
in an area of perennial transmission at the time of vacci-
nation with DPT2, DPT3 and measles vaccines reduced
the incidence of clinical malaria and anaemia during the
first year of life by 59% and 50% respectively. Further-
more, protection against clinical episodes of malaria per-
sisted into the second year of life [3]. In contrast, in
northern Ghana, where malaria transmission is intense
and highly seasonal, SP-IPTi gave only 25% protection
against clinical malaria and 35% protection against hospi-
tal admissions with anaemia during the first year of life
and no protection during the second year [4]. A similar
level of protection against clinical malaria during the first
year of life was seen in Mozambique but no protection
against anaemia was detected in this study [5]. Further tri-
als of SP-IPTi conducted in areas of Ghana [6,7] and
Gabon [8] with differing epidemiological patterns of
malaria have given similar results to those observed in
Ghana and Mozambique. The results from the first study
in Tanzania therefore appear at odds with those from the
later studies.
A number of explanations for the differences in protective
efficacy (PE) of IPTi against clinical malaria between sites
has been suggested including the intensity of transmission
and consequent malaria incidence, the pattern of antima-
larial resistance, the administration of iron and the use of
additional control measures, specifically insecticide-
treated nets (ITN) [9]. This paper, using data from the six
SP-IPTi randomized placebo-controlled trials reported so
far, explored the association between resistance to SP, ITN
coverage and malaria transmission intensity in each study
site. The observed PE of IPTi against clinical malaria is
examined using a mathematical model which mimics the
acquisition and loss of parasites to predict the PE expected
in the six trial settings.
Methods
Data
Data are from IPTi trials conducted in Manhiça (Mozam-
bique), Lambarene (Gabon), Ifakara (Tanzania) and Nav-
rongo, Kumasi and Tamale (Ghana). Detailed
descriptions of the study population, methodology and
outcome in each study included in this analysis have been
published elsewhere [2-8]. A summary of the study
designs and their epidemiological background is shown
in Table 1. The model output was compared to data
derived from the IPTi Consortium's Statistical Working
Group (SWG) Report of September 2007. The SWG used
common definitions for time at risk and for an episode of
clinical malaria across all six studies. For time at risk a
child treated for clinical malaria was censured for 21 days
in order to prevent double counting of cases and to allow
for any prophylactic effect of the antimalarial. A case of
clinical malaria was defined as measured fever or history
of fever with any parasitaemia of P. falciparum (definition
of duration of history of fever differed between studies: for
Ifakara and Manhica studies it was 24 hours and for
remaining studies it was 48 hours). In this paper, all refer-
ences to the PE of IPTi refers to the PE against episodes of
clinical malaria up to 12 months of age based on inci-
dence rates of multiple episodes of clinical malaria, not
time to first or only episodes.
The relationship between the observed PE of IPTi and the
following potential determinants of PE were explored:
resistance to SP; estimated ITN coverage (% of the study
population reporting use of ITN); and malaria transmis-
sion intensity (mean incidence of malaria per child per
Table 1: Study characteristics of SP-IPTi efficacy trials
Study parameter Schellenberg et al. 
[2, 3]
Chandramohan et 
al. [4]
Macete et al [5] Kobbe et al. [6] Mockenhaupt et al. 
[7]
Grobusch et al [8]
Trial, country Ifakara, Tanzania Navrongo, Ghana Manhica, Mozambique Kumasi, Ghana Tamale, Ghana Lambaréné, Gabon
Recruitment year(s) 1999–2000 2000–2002 2002–2004 2003–2005 2003 2004–2005
EIR/year 29 418 38 400 NA 50
Transmission Perennial moderate Highly seasonal high Perennial with 
seasonal peaks 
moderate
Perennial high Perennial with 
seasonal peaks high
Perennial with 
seasonal peaks low-
moderate
In vivo SP resistance by 
day 14%
31 (1999–2000) [10] 22 (2004) [11] 21 (2001) [12] NA 14 (2002) [14] 21 (2004) [13]
Use of bed nets, % 
placebo/SP treated 
(untreated)
67/68 17/19 0/0 (14/15) 20/20 estimate
 (39/38)
<1% 5/5 (80/80)
Iron supplementation Yes Yes None None None None
Ages at dosing, 
months
2, 3, 9 (at time of 
DPT2, DPT3 & 
measles)
3, 4, 9, 12 (at time of 
DPT2, DPT3 & 
measles + extra at 12 
months)
3, 4, 9 (at time of 
DPT2, DPT3 & 
measles)
3, 9, 15 (at time of 
DPT3 & measles + 
extra at 15 months)
3, 9, 15 (at time of 
DPT3 & measles + 
extra at 15 months)
3, 9, 15 (at time of 
DPT3 & measles + 
extra at 15 months)
No. of children 
enrolled, placebo/
active
351/350 = 701 1,242/1,243 = 2,485 755/748 = 1,503 535/535 = 1,070 600/600 = 1,200 595/594 = 1,189
Study design Individual 
randomization
Cluster 
randomization
Individual 
randomization
Individual 
randomization
Individual 
randomization
Individual 
randomizationPage 2 of 13
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Malaria Journal 2008, 7:54 http://www.malariajournal.com/content/7/1/54year in the placebo group). Day-14 parasitological and
clinical failure rates were used to define resistance because
five out of the six IPTi trials had published this informa-
tion within two years of conducting the IPTi trial [10-14].
One site in Ghana, Kumasi, did not have data on day 14
parasitological and clinical failure of SP and therefore the
estimate from Tamale, relatively close geographically, was
used.
Mathematical model
An age-structured model (Figure 1) was developed to rep-
resent the acquisition of malaria infection and clinical dis-
ease and the development of immunity in the study
cohort of infants between the ages of two and 24 months.
The modelling exercise only examines the specific cohort
as studied in the trials, thus age and calendar times are
equivalent and the model output is expressed in terms of
the age of the children. At any point in time children can
be in one of two states – uninfected and susceptible to
new infection S(a) or infected with parasites which can
remain asymptomatic or can become symptomatic, A(a).
It is assumed that the rate of acquisition of new infections
is determined by the force of infection in the study area,
λ(a), which may vary through time (and hence by age).
Once infected and in the asymptomatic state, children
return to the susceptible state through one of three routes.
First, they may become a clinical case and receive an effec-
tive treatment. It is assumed that in clinical trial settings,
every case of malaria detected was adequately treated and
parasites cleared. Secondly, they may receive antimalarial
treatment for asymptomatic parasitaemia eg IPTi. Finally,
they may remain asymptomatic and recover naturally.
Symptomatic cases of malaria that are not detected by sur-
veillance systems will remain in the asymptomatic state in
the model until they die of severe disease or their immune
response clears parasites. The model does not incorporate
children leaving the asymptomatic pool by death, assum-
ing this will be a very small number because most of the
cases would be detected in time to receive effective treat-
ment in a trial setting.
Ignoring mortality from other causes and migration, the
model without interventions can be expressed by the fol-
lowing equation:
where N is the fixed population size, r(a) is the age-
dependent rate of natural clearance of parasitaemia and
c(a) is the age-dependent rate of development of clinical
disease which is then treated.
In endemic areas the risk of developing clinical disease
decreases with exposure to infection but rates of parasitae-
mia remain almost constant in early childhood. The
model incorporates functions that mimic the develop-
ment of immunity so that as children age the rate at which
they develop clinical disease decreases and the rate at
which they clear parasites increases. For simplicity, the
model assumes that both immunity functions are linearly
dependent on the expected number of malaria infections
at age a:
δ α
δα λ α α χ α ρ α α
Α Ν Α Α( ) = ( )( − ( )) − ( ( ) + ( )) ( ) (1)
E I a
N
a S a da
a
[ ( )] ( ’) ( ’) ’= ∫1
0
λ (2)
The asymptomatic parasite pool modelFigure 1
The asymptomatic parasite pool model.
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Malaria Journal 2008, 7:54 http://www.malariajournal.com/content/7/1/54The rate of development of clinical disease is given by the
logistic function
where ϕ is the rate of development of clinical disease in
the absence of immunity and α1 and α2 are parameters
which determine the number of infections after which full
immunity to clinical disease occurs. The rate of natural
clearance of parasites is assumed to be linear within the
range of interest and hence is given by
r(a) = min(ωE [I(a)], 1)) (4)
where 1/ω is the mean number of infections after which
full parasite immunity is obtained and it was assumed
that at full immunity parasites are cleared after a mean of
one day.
A generic maternal protective function which acts to
reduce the force of infection following birth was incorpo-
rated. Maternal protection is complicated and multifac-
eted [15], incorporating both biological immunity as well
as behavioural factors that limit exposure. Given the pau-
city of data with which to determine an appropriate func-
tion, the following factors were used, which act on the
force of infection up to six months of age: 0.05, 0.15, 0.4
and 0.8 at age 2, 3, 4 and 5 months of age respectively,
which represent a gradual loss of immunity.
The model was numerically evaluated as difference equa-
tions in 1-month time-steps using Excel.
Incorporation of IPT and ITN
To compare the model results to the trial data the two
interventions were incorporated. Firstly, use of ITNs is
included by reducing the force of infection in the group
assigned to ITNs by a factor θ:
The model only examines the personal protection gained
from an ITN and does not examine any other effects, such
as effects on transmission.
IPT use across all age-groups modelled (two to 24
months) is assumed to act in three ways, clearing parasites
in a proportion (1-σ) of the population, ie the treatment
effect, prophylaxes against new infection (factor σ reduc-
ing the force of infection) and reducing the rate of devel-
opment of clinical disease by the same factor. As the
model is defined in monthly time-steps, the parameter σ
can be interpreted as the PCR uncorrected day 28 Ade-
quate Clinical and Parasitological Response (ACPR)
which measures the proportion that will clear parasitae-
mia and be protected against new infection 28 days post
treatment. For simplicity, it was assumed that the ACPR
acts with equal efficacy to clear parasites, to protect against
new infection and prevent development of disease.
Equation (6) is applied to the model only for months
when IPTi doses are given. For months in those children
who used ITNs and receive IPT equations (5) and (6) are
combined.
For the modelling exercise, the coverage of ITNs (reported
ownership) in each trial site was used because the use of
ITN at the individual level was not available for all trials.
The expected incidence of clinical disease in each trial arm
(placebo and IPT) is therefore calculated as a weighted
combination of the model predictions with and without
ITNs. The protective efficacy of IPT predicted by the model
is calculated as 1-relative risk = 1-clinical incidence in IPTi
group/clinical incidence in placebo group.
Model parameters
It is assumed that that on average after 5 infections of
malaria an individual is totally protected against clinical
disease and that after 50 infections an individual can clear
parasites rapidly. A sensitivity analysis for these parame-
ters can be found later in this paper. Parameters that
reproduce these patterns are given in Table 2. The force of
infection, λ(a) was assumed to be constant for the base-
line scenarios. At a later stage the modelling exercise used
scenarios in which the force of infection was decreased in
early childhood due to maternal protective factors and
separately allowed to increase or decrease linearly as the
children aged reflecting changes in transmission over
time. The force of infection was initially estimated directly
as the mean incidence of clinical malaria in the placebo
group. This approximation was based on the observation
that the age-specific incidence of clinical malaria is high-
est in infants, the IPTi target age group and that the age
group with the highest incidence should have the lowest
immunity. The observed data from the Navrongo study
(the only full dataset available to the study team) was
compared with the model estimates of clinical disease,
which were found to be half of that observed in the study.
Thus, the mean incidence of clinical malaria in the pla-
cebo group was multiplied by a factor of two to estimate
the force of infection. Entomological Inoculation Rates
(EIR) were not used as a measure of transmission in the
model for two reasons: EIRs measured concurrently with
the IPTi trials were not available for most sites and in the
c a
e E I a
( )
[ ( )]
=
+
+
ϕ α
α α
1 1
1 2
(3)
dA a
da
a N A a c a r a A a
( )
( ) ( )( ( )) ( ( ) ( )) ( )= − − − +1 θ λ
(5)
dA a
da
a N A a c a r a A a A a
( )
( ) ( )( ( )) (( ) ( ) ( )) ( ) ( )= − − − − + −1 1σ λ σ σ
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Secondly, these large cohort studies had enrolled children
from a large geographical area over several years (two to
four years). Thus a single measure of EIR would not suffice
to represent the whole study area or the whole study
period.
The proportion of infected children becoming sympto-
matic and treated in the absence of immunity was
assumed to be 90% in one month. This was derived from
a study of asymptomatic parasitaemia in 6–59 month old
children in a moderate malaria setting in Kampala,
Uganda [16]; in this population 50% of children with
asymptomatic parasitaemia developed clinical malaria
after 30 days. As the Ugandan study was undertaken in
partially immune children we assumed a higher rate of
development of disease. Clinical malaria cases are
assumed to recover within a month post treatment, twice
the average terminal half-life of the antimalarials used for
treatment and rejoin the susceptible population. Deaths
and migrations were not included in the model.
For those children receiving IPT, it is assumed that treat-
ment, prophylaxis, and prevention of developing clinical
disease effects of SP will be equally affected by the PCR
uncorrected day 28 ACPR of SP. Day 28 PCR uncorrected
ACPR is a measure of both the treatment and prophylactic
effect combined (it includes both recrudescence's and re-
infections) and is more likely to represent the effects of the
drugs when used for prevention as opposed to treatment.
The sensitivity analysis for how changes in ACPR affect PE
is shown in the in the results section. Briefly, as drug resist-
ance increases PE declines. The day 28 ACPR was only
available for 2 sites, the sites with the highest and lowest
resistances at day 14, namely Ifakara [10] and Tamale [14]
respectively. The extrapolation from day 14 to 28 efficacy
for the 3 studies [11-13] without day 28 ACPR is the mid
point between these two studies.
For those children using ITNs, we assume that the protec-
tive efficacy of an ITN is 0.5 [17]. The model parameters
are summarised in Table 2.
Sensitivity analysis
A sensitivity analysis of how ACPR, ITN coverage and
immunity functions affects predicted PE was carried out.
Results
Association between IPTi protective efficacy and various 
factors
Figure 2 shows the relationship between PE of IPTi and
resistance to SP, estimated ITN coverage, and malaria
transmission intensity in each study site. The Ifakara study
site had the highest IPTi PE (59%) despite having the
highest resistance to SP (31% day-14 parasitological and
clinical failure rate). This site also had the highest ITN cov-
erage (67%). Resistance to SP was 14 – 22% and ITN cov-
erage was 0 – 20% in the other five sites.
Protective efficacy of IPTi in stable transmission settings
The model predicted a similar pattern across the six trials,
with a transient decline in incidence among the groups
receiving IPTi (with and without ITN coverage) as well as
a generally lower incidence among groups with ITNs
(with and without IPTi). Using the Navrongo study as an
example (IPTi doses given at 3, 4, 9 and 12 months of
age), Figure 3 shows the models prediction of monthly
incidence of clinical disease cases in groups with and
without ITNs (Figure 3A), the combined model weighted
by ITN coverage (Figure 3B) and observed data from the
Navrongo [18] study for comparison (Figure 3C). In those
trial settings with higher incidence the model generates a 
Table 2: Summary of Model Parameters and Symbols
Parameter Description Parameter Symbol Value
Definitions for equations
Susceptible population at age (a) S(a) N/A
Asymptomatic population at age (a) A(a) N/A
Age-dependent rate of natural clearance of parasitaemia at age (a) r(a) N/A
Age-dependent rate of development of clinical disease which is then treated at age (a) c(a) N/A
Protective Efficacy PE N/A
Fixed parameters
Rate of development of clinical disease in the absence of immunity φ 0.9
Mean number of infections after which full immunity to clinical disease occurs μ 5
Parameters which determine the number of infections after which full immunity to clinical disease occurs α1 and α2 1
Mean number of infections after which full parasite immunity occurs ω 50
Protection offered by ITN use θ 0.5
Variable parameters between sites
Force of infection λ(a) See table 3
Drug action reducing the force of infection σ See table 3Page 5 of 13
(page number not for citation purposes)
Malaria Journal 2008, 7:54 http://www.malariajournal.com/content/7/1/54
Page 6 of 13
(page number not for citation purposes)
Protective efficacy of IPTi at 12 months of age compared to estimated resistance to SP at Day 14, ITN coverage and incidence of malaria in pl eb  groupsFigure 2
Protective efficacy of IPTi at 12 months of age compared to estimated resistance to SP at Day 14, ITN cover-
age and incidence of malaria in placebo groups.
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rongo study [18] (by kind permission of Tropical Medicine and International Health, Blackwell Publishing). 
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Malaria Journal 2008, 7:54 http://www.malariajournal.com/content/7/1/54IPTi dose due to delayed acquisition of immunity which
continues into the second year of life (the rebound effect).
The predicted PE of IPTi in the six sites with the observed
data are shown in Table 3. The mean ratio between model
to actual PE was 1.02 (range 0.39 – 1.59) with the pre-
dicted PE lying within the 95% confidence interval from
the trial data in all but the Ifakara study. The main differ-
ences between the Ifakara and the other studies were the
high ITN coverage and the higher resistance to SP. There
seems no obvious explanation to why IPTi should be
more effective with higher drug resistance. However, high
ITN coverage may have an effect on transmission. Thus
the effect of changing transmission on the PE predicted by
the model is further explored.
Protective efficacy of IPTi in changing transmission 
settings
Table 4 shows the change in both PE and the effect of
delayed immunity (rebound effect) predicted by the
model for Ifakara under four scenarios with changing
transmission during the study period with both maternal
immunity function removed and included – (a) increas-
ing at a rate of 25% per month, (b) increasing at a rate of
5% per month, (c) stable, (d) a decline of 5% per month
and (e) a decline of 25% per month. In the scenarios of
changing transmission, PE is dominated when the effect
of IPTi is most efficacious, ie when transmission is high-
est. In the output of the model without the maternal
immunity function (Figure 4A) the overall PE measured
by the trial is dominated by its early efficacy with the first
two doses of IPTi. Thus, because most of the efficacy is
predicted to occur during the months in which doses are
given (at 2, 3 and 9 months of age in this trial), the meas-
ured overall PE is high. Conversely, if transmission is
increasing then the overall measure of PE will be domi-
nated by what is happening during the later months when
doses are no longer being given and hence a lower overall
protective efficacy will be estimated. When including the
maternal immunity function (Figure 4B) the 3rd dose of
IPTi given at nine months of age has the dominant effect
on the PE. Changes in transmission affect the extent to
which rebound or prolonged protection are observed in
the months following the IPTi doses independently of
maternal immunity. If overall transmission is being
reduced, this in turn reduces the probability of infection
once the direct protection afforded by IPTi is removed and
hence reduces the potential for the rebound effect to be
observed and increases the probability of observing pro-
longed protection.
Sensitivity analysis
The results of the sensitivity analysis of ACPR are shown
in Table 5. PE increases when the ACPR is high (i.e. there
is little resistance) as the IPT effect is greatest under this
scenario and visa versa. Varying ITN coverage from
0–100% had little effect on predicted PEs of the trials
(range of variation of PE from baseline (results shown in
Table 3): 0–0.6%). Increasing the mean number of infec-
tions to become immune against clinical disease from 5 to
10 reduced predicted PE but the magnitude was small
(range of variation of PE from baseline: 0.3–0.8%). Vary-
ing the effect of number of infections to get anti-parasite
immunity also had little effect on predicted PE (range of
number attacks required to get anti-parasite immunity:
20–100, range of variation of PE from baseline: 0–0.3%).
The maternal immunity function greatly affected pre-
dicted PE. Table 6 shows the effect on PE when (a) no
immunity is predicted, (b) the models fixed non-paramet-
ric form is used (baseline) and (c) a function of maternal
immunity against severe disease published elsewhere
[19]. Without maternal immunity PE is enhanced.
Discussion
The high PE of IPTi found in the Ifakara study and a sim-
ilar preventive trial using amodiaquine in north-eastern
Tanzania [20] triggered a series of IPT trials in other Afri-
can study sites to investigate this potentially promising
Table 3: Modelled and actual protective efficacy to 12 months of age in each IPTi trials
Input Output
Study Site Age of SP IPTi 
administration 
(months)
Mean incidence in 
placebo group (epi-
sodes per person 
year) (λ(a)/2)
ITN 
coverage 
(%)
Estimated*** cross 
sectional 
prevalence 
parasitaemia at 
start of study (%)
Estimated Day 
28 ACPR for 
SP (σ × 100)
Model 
estimate of PE 
(%)
Actual PE of 
IPTi (% 95% CI)
Ratio 
model:study
Ifakara 2,3 and 9 0.54 67 4.5 60 23.0 58.8 (40.8–71.3) 0.39
Navrongo 2,4,9 and 12 1 18 8.3 65* 31.9 29.3 (17.7–39.5) 1.09
Mahnica 3,4 and 9 0.71 0 5.9 65* 32.0 20.1 (2.1–34.9) 1.59
Kumasi 3,9 and 15 1.27 20 10.6 69** 25.9 20.9 (8.9–31.3) 1.24
Tamale 3,9 and 15 0.93 1 7.8 69 24.9 33.3 (20.7–43.8) 0.75
Lamberene 3,9 and 15 0.16 5 1.3 65* 23.7 22.0 (-25.4–51.5) 1.08
* Estimated from Day 14 ACPR, ** Estimated from Tamale data.
*** Starting Cross sectional parasite prevalence (asymptomatic infected children) estimated from mean monthly incidence in placebo group Incidence and PE figures from IPTi 
Consortium Statistical Working Group Report September 2007 (Aponte JJ et al. In preparation)Page 8 of 13
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Malaria Journal 2008, 7:54 http://www.malariajournal.com/content/7/1/54method of malaria control. Subsequent published trials
showed a much lower efficacy of IPTi than was observed
in Ifakara [2]. To explain these differences in efficacy
between sites some observers have focussed on the differ-
ences in drug resistance to SP between the sites. However,
this explanation does not appear plausible because the
site with the highest PE had the highest SP resistance (Fig-
ure 2). In response to this observation, it has been sug-
gested that there may be an immunisation effect of SP, the
"Leaky Drug" theory [3,21]. The hypothesis is that a par-
tially effective drug allows for low level and persisting par-
asitaemia and thus allowing prolonged stimulation of the
immune system resulting in the extended period of pro-
tection as seen in the Ifakara site. This model-based anal-
ysis provides an alternative explanation, namely that the
exceptionally high ITN coverage in Ifakara decreased
transmission and boosted the observed PE of IPTi. High
ITN coverage was recognised as a potential explanation of
differences in PE between the Manhica and Ifakara studies
[9]. Ifakara District is known to have experienced a 10 fold
reduction in transmission around the study period (for
example, the EIR in 1995 was recorded as 300 and by
2001 had fallen to 29). Although the EIR estimates came
from different places within the district there was a
reported change in the epidemiology of clinical disease
during this time period [22]. In addition many other stud-
ies have shown the mass effect on transmission of high
ITN coverage [17]. The model suggests that changing the
transmission intensity affects both the PE and the length
of protection and thus gives a plausible explanation for
the difference in results between study sites. Another
modelling exercise focussing on the mechanism of IPTi
(Ross A., manuscript in preparation) has confirmed this
finding. No clear decrease was seen in the mean incidence
of clinical malaria in the placebo arm of the Ifakara study
from the published data from the first [2] to the second
[3] year, going from 0.43 to 0.42 episodes per person year
at risk. The model predicts that over the first year of the
study transmission must fall by at least 22% per month to
be within the 95% confidence limits of the PE observed.
Whilst this seems unlikely, the pattern of transmission
faced by the cohort may have changed within the observa-
tion period and affected the observed PE. To test the
hypothesis derived from this model the data will need to
be examined by looking at monthly incidence in each
group by age in the Ifakara study.
The model shows that PE mainly depends on the level of
malaria transmission during the few months which IPTi
doses are administered and the length of follow up and
transmission intensity when IPTi is not given. To maxim-
ise PE IPTi should be given during high malaria transmis-
sion and follow up should be short when malaria
transmission is low. Supportive evidence for this is dem-
onstrated in the extended analysis of the Navrongo study
[18] and an IPT seasonal study where antimalarials were
given in Senegal, West Africa during the malaria seasons
with a short follow up of 13 weeks [23]. In this study effi-
cacy against clinical malaria was 86%.
This model also provides a coherent explanation as to
why no rebound effect would be observed in situations of
decreasing transmission, such as Ifakara or Kenya [24,25].
The delay in acquisition of immunity caused by very suc-
cessful interventions such as continuous chemoprophy-
laxis in infants are followed by increases in cases
following cessation of the intervention, the rebound effect
[26-28]. In this situation of chemoprophylaxis in a single
age group there is no effect on transmission. However, in
the large ITN trials where no rebound was seen, the mass
effect of the ITNs in reducing vectorial capacity led to a
decrease in transmission [17]. The model predicts that in
the presence of decreasing transmission rebound parasi-
taemia can disappear. Thus, although the population is
immunologically more susceptible to infection with
malaria, it is less exposed and so cases of malaria infection
Table 4: Change in Protective Efficacy and rebound effect with changes in transmission
Transmission Transmission effect per 
month (%)
Predicted protective efficacy 
over first 12 months (%)
Protection until Rebound effect
No maternal immunity
Fast increase 1.25 (25) 27.1 12 months Yes
Increasing 1.05 (5) 29.2 12 months Yes
Stable 1 (0) 30.6 13 months Yes
Slow decline 0.95 (5) 32.2 13 months No
Fast decline 0.75 (25) 42.8 > 24 months No
Maternal immunity included
Fast increase 1.25 (25) 22.7 12 months Yes
Increasing 1.05 (5) 22.1 13 months Yes
Stable 1 (0) 23.0 14 months Yes
Slow decline 0.95 (5) 22.7 14 months No
Fast decline 0.75 (25) 23.1 16 months NoPage 9 of 13
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Model predictions of Ifakara Tanzania IPTi study without (A) and including (B) maternal immunity function with different changes in transmissionFigur  4
Model predictions of Ifakara Tanzania IPTi study without (A) and including (B) maternal immunity function 
with different changes in transmission.
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Malaria Journal 2008, 7:54 http://www.malariajournal.com/content/7/1/54reduce. In contrast, when an intervention that reduces
exposure and hence immunity to malaria takes place in a
site with stable malaria transmission or one in which
transmission is increasing a rebound effect would be evi-
dent. If IPT was spread across all age groups, ie as a form
of mass drug administration or universal IPT (IPTu)
reducing the asymptomatic pool (A(a) in the model) in
the whole population and not a small age group, an effect
on transmission may be seen.
ITNs exert a steady personal protection to the individual
sleeping under the net of approximately 50% [17] as long
as the insecticide remains active. IPTi offers intermittent
protection which varies with the efficacy of the drug only
at times when it is administered. Therefore it follows that
protection with an ITN should be the primary interven-
tion with IPTi as an additional strategy. The model found
the largest difference in incidence of clinical malaria
between placebo groups without ITN compared to ITN
plus IPTi. This observation suggests that combining inter-
ventions must be a priority. ITN coverage has little influ-
ence on the predicted PE by the model. This is because the
model defines the protection of an ITN to act to reduce the
force of infection to the proportion of those using ITNs
and then calculates the overall PE weighted by this cover-
age. The model assumes an additive effect of IPTi and
ITNs and not synergy.
As with all theoretical studies, the model has some limita-
tions. The model is dependent on some key assumptions
regarding the effect of exposure on immunity. First, it is
assumed that full clinical immunity was obtained after
five infections. This figure was derived from past estimates
for severe malaria [19] but clearly requires further data for
verification. Increasing the number of infections required
to become immune to developing clinical disease would
result in a smaller rebound effect and a smaller decrease in
transmission would eliminate the rebound effect. No
clear evidence for rebound has been seen in the trials [29],
thus the number of clinical attacks leading to immunity is
likely to be more than five. Similarly, the threshold for
achieving parasite immunity was arbitrarily set at 50 infec-
tions. However, as the model only considers malaria in
the first 2 years of life, children are unlikely to reach the
five attacks needed to become immune to clinical disease
(mean number of expected attacks in Kumasi, the highest
transmission setting, was 2.7 at 24 months of age) and
even less likely to reach the 50 attacks to give full antipar-
asite immunity, the results are less sensitive to these
choices of immune function. Whilst the choice of immu-
nity functions determines the extent of the rebound effect
predicted by the model, it does not impact greatly on the
protective efficacies predicted by the model. In contrast,
the assumptions made regarding maternal protection do
impact on the predicted protective efficacy (Tables 4 and
6, Figure 4A and 4B). The effect of maternal protection is
likely to vary by site and be influenced by levels of trans-
Table 5: Sensitivity analysis of effects of ACPR on models predictions of PE
Study Site Observed PE (%, 95% CI) Model PE (%)
Baseline ACPR increased to 100% ACPR reduced to 40%
Ifakara 58.8 (40.8–71.3) 23.0 37.5 15.5
Manhica 20.1 (2.1–34.9) 32.0 47.4 20.2
Navrongo 29.3 (17.7–39.5) 31.9 47.3 20.1
Lamebarene 22.0 (-25.4–51.5) 23.6 36.4 14.5
Kumasi 20.9 (8.9–31.3) 25.9 36.9 15.3
Tamale 33.3 (20.7–43.8) 24.9 36.5 14.3
Table 6: Sensitivity analysis of maternal immunity function on models predictions of PE with (a) no maternal immunity function, (b) 
with fixed non-parametric function used in the paper (Baseline) and (c) function based on maternal immunity to severe disease.
Study Site Observed PE (%, 95% CI) Model PE (%)
(a) No immunity (b) Baseline (c) Alternative based on immunity to severe disease
Ifakara 58.8 (40.8–71.3) 32.4 23.0 26.4
Manhica 20.1 (2.1–34.9) 38.6 32.0 34.0
Navrongo 29.3 (17.7–39.5) 38.5 31.9 34.1
Lamebarene 22.0 (-25.4–51.5) 28.2 23.6 26.0
Kumasi 20.9 (8.9–31.3) 38.0 25.9 30.3
Tamale 33.3 (20.7–43.8) 29.7 24.9 27.4Page 11 of 13
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cental passage of humoral immunity and behavioural
factors. Further data are required to refine this function.
Differences in calculating time at risk following treatment
also bias the model to detect a higher PE. In the analysis
used to produce the PEs in the studies, a child was cen-
sored for 21 days after each case of malaria yet the model
uses one month time steps and so cases of malaria are cen-
sored seven days longer, reducing the time at risk denom-
inator. The model studies very few variables and only
those directly affecting malaria. The differences of the PEs
in the studies could be related to factors so far remaining
unstudied such as HIV prevalence, socio-economic status,
timing and dose of IPTi, heterogeneity of malaria trans-
mission or placental infection.
What does this study mean for IPTi? This model demon-
strates that during a decline in malaria transmission,
which Africa is currently experiencing, IPTi can be highly
effective and safe. Combining IPTi with ITNs results in
greater protection for an individual, further more, if high
levels of coverage of ITNs can be attained with a resultant
decrease in transmission, then there appears to be synergy
between the interventions. However, if transmission sub-
sequently increases a reduction in the efficacy of IPTi (as
currently measured by comparing incidence rates of
malaria over a long period) can be expected. In stable con-
ditions, PE does not seem to be greatly affected by levels
of transmission, however the higher the level of transmis-
sion the more likely a rebound effect is to be seen. The
rebound effect is equivalent to delaying of clinical cases of
malaria to an older age which may be beneficial as older
children appear to develop less severe illness than infants
[28]. Indeed, these observations will apply to all types of
interventions during times of changing transmission
intensity. Currently there is a reduction of transmission
across sub-Saharan Africa [30], thus exposure and immu-
nity will be reduced leaving the possibility for outbreaks
of malaria disease should transmission increase again.
Drug resistance does play a role in IPTi efficacy and this
should continue to be monitored. However, changes in
transmission are likely to have a greater effect on IPTi pro-
tective efficacy in the trials that have taken place with the
levels of drug resistance studied.
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